Infectious Disease
Infectious Disease(传染病)
Infectious Disease 相关产品(1138)
- GC52119Lansoprazole sulfone N-oxideCAS: 953787-54-7纯度: >98.00%
A potential impurity found in commercial preparations of lansoprazole
- GC521293-Amino-5-hydroxybenzoic AcidCAS: 76045-71-1纯度: >98.00%
A biosynthetic precursor to ansamycin antibiotics
- GC52171Clindamycin-d3 (hydrochloride)CAS: 1356933-72-6纯度: >99.00%
An internal standard for the quantification of clindamycin
- GC52174Sulfadoxin-d4CAS: 1330266-05-1纯度: >99.00%
An internal standard for the quantification of sulfadoxin
- GC522117-[1-(1H)-Tetrazolylacetamido]desacetoxycephalosporanic AcidCAS: 56842-77-4纯度: >95.00%
A potential impurity in commercial preparations of cefazolin
- GC52224(±)-MMT5-14CAS: 2719679-31-7纯度: >98.00%
A derivative of remdesivir with antiviral activity
- GC52261Entecavir-d2CAS: 142217-69-4纯度: >99.00%
An internal standard for the quantification of entecavir
- GC52303Ethyl MycophenolateCAS: 32483-51-5纯度: >98.00%
A potential impurity found in commercial preparations of mycophenolate mofetil
- GC523243-(3-Hydroxyphenyl)propionic Acid sulfateCAS: 86321-32-6纯度: >95.00%
A metabolite of certain phenols and glycosides
- GC52326Biotin-PEG4-LL-37 (human) (trifluoroacetate salt)纯度: >90.00%
A biotinylated and pegylated form of LL-37
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC52088 | Methylchloroisothiazolinone (hydrochloride) | 26530-03-0 | >95.00% | |
A biocide | ||||
| GC52095 | Dodecyltrimethylammonium (bromide) | 1119-94-4 | >98.00% | |
A cationic surfactant | ||||
| GC52101 | Brazilein | 600-76-0 | >95.00% | |
A phytochemical with diverse biological activities | ||||
| GC52119 | Lansoprazole sulfone N-oxide | 953787-54-7 | >98.00% | |
A potential impurity found in commercial preparations of lansoprazole | ||||
| GC52120 | DMPE-MPEG(2000) | 1254157-61-3 | >90.00% | |
A PEGylated form of DMPE | ||||
| GC52127 | Pexiganan (acetate) | 172820-23-4 | >98.00% | |
An antimicrobial peptide | ||||
| GC52129 | 3-Amino-5-hydroxybenzoic Acid | 76045-71-1 | >98.00% | |
A biosynthetic precursor to ansamycin antibiotics | ||||
| GC52133 | 12-Tridecenoic Acid | 6006-06-0 | >95.00% | |
A monounsaturated fatty acid | ||||
| GC52165 | Minosaminomycin | 51746-09-9 | >90.00% | |
An antibiotic | ||||
| GC52171 | Clindamycin-d3 (hydrochloride) | 1356933-72-6 | >99.00% | |
An internal standard for the quantification of clindamycin | ||||
| GC52174 | Sulfadoxin-d4 | 1330266-05-1 | >99.00% | |
An internal standard for the quantification of sulfadoxin | ||||
| GC52191 | Deacetylanisomycin | 27958-06-1 | >95.00% | |
A derivative of anisomycin | ||||
| GC52211 | 7-[1-(1H)-Tetrazolylacetamido]desacetoxycephalosporanic Acid | 56842-77-4 | >95.00% | |
A potential impurity in commercial preparations of cefazolin | ||||
| GC52224 | (±)-MMT5-14 | 2719679-31-7 | >98.00% | |
A derivative of remdesivir with antiviral activity | ||||
| GC52230 | AA3-DLin | - | >95.00% | |
An ionizable cationic amino lipid | ||||
| GC52240 | BPH-1358 | 5352-53-4 | >95.00% | |
An inhibitor of UPPS and FPPS | ||||
| GC52253 | α-Enolase (1-19)-biotin Peptide | - | - | |
A biotinylated α-enolase peptide | ||||
| GC52261 | Entecavir-d2 | 142217-69-4 | >99.00% | |
An internal standard for the quantification of entecavir | ||||
| GC52272 | Jun9-72-2 | 2657659-42-0 | >98.00% | |
A SARS-CoV-2 PL pro inhibitor | ||||
| GC52291 | KAS 08 | 203861-20-5 | >95.00% | |
A STING activator | ||||
| GC52303 | Ethyl Mycophenolate | 32483-51-5 | >98.00% | |
A potential impurity found in commercial preparations of mycophenolate mofetil | ||||
| GC52315 | GK241 | 1899930-93-8 | >98.00% | |
An sPLA 2 (Type IIA) inhibitor | ||||
| GC52324 | 3-(3-Hydroxyphenyl)propionic Acid sulfate | 86321-32-6 | >95.00% | |
A metabolite of certain phenols and glycosides | ||||
| GC52326 | Biotin-PEG4-LL-37 (human) (trifluoroacetate salt) | - | >90.00% | |
A biotinylated and pegylated form of LL-37 | ||||